Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

Table 2 Inhibition of the Activity of Wild-Type Kit and Primary Activating Kit Mutants by Motesanib and Imatinib*

	IC₅₀ of Kit Autophosphorylation, nM		IC₅₀ of Stably Transfected Ba/F3 Cell Survival, nM
*KIT Genotype*	Motesanib	Imatinib	Motesanib	Imatinib
Wild-type	36	165	-	-
V560D	5	18	3	7
Δ552-559	1	5	0.4	1
AYins503-504	18	84	11	47

*In autophosphorylation experiments, means from 2 experiments are shown, with the exception of Δ552-559, which was assessed once. Viability experiments were performed once.

ISSN: 1756-9966